Vaxxinity Stock Performance
| VAXX Stock | USD 0.0004 0.0001 33.33% |
Vaxxinity holds a performance score of 31 on a scale of zero to a hundred. The entity has a beta of -72.78, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Vaxxinity are expected to decrease by larger amounts. On the other hand, during market turmoil, Vaxxinity is expected to outperform it. Use Vaxxinity maximum drawdown, skewness, as well as the relationship between the Skewness and price action indicator , to analyze future returns on Vaxxinity.
Risk-Adjusted Performance
High
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Vaxxinity are ranked lower than 31 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Vaxxinity showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Vaxxinity |
Vaxxinity Relative Risk vs. Return Landscape
If you would invest 1.00 in Vaxxinity on October 8, 2025 and sell it today you would lose (0.96) from holding Vaxxinity or give up 96.0% of portfolio value over 90 days. Vaxxinity is currently generating 149.1093% in daily expected returns and assumes 373.6552% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Vaxxinity, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vaxxinity Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vaxxinity's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Vaxxinity, and traders can use it to determine the average amount a Vaxxinity's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.3991
| Best Portfolio | Best Equity | VAXX | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Vaxxinity is performing at about 31% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vaxxinity by adding it to a well-diversified portfolio.
Vaxxinity Fundamentals Growth
Vaxxinity Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Vaxxinity, and Vaxxinity fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vaxxinity Pink Sheet performance.
| Return On Equity | -1.51 | |||
| Return On Asset | -0.48 | |||
| Current Valuation | (1.39 M) | |||
| Shares Outstanding | 112.91 M | |||
| Price To Book | 4.58 X | |||
| Price To Sales | 4,605 X | |||
| EBITDA | (56.05 M) | |||
| Cash And Equivalents | 128.23 M | |||
| Cash Per Share | 1.02 X | |||
| Total Debt | 15.17 M | |||
| Debt To Equity | 0.09 % | |||
| Book Value Per Share | 0.11 X | |||
| Cash Flow From Operations | (57.24 M) | |||
| Earnings Per Share | (0.45) X | |||
| Total Asset | 44.35 M | |||
| Retained Earnings | (361.64 M) | |||
About Vaxxinity Performance
Evaluating Vaxxinity's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Vaxxinity has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vaxxinity has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas. Vaxxinity Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people.Things to note about Vaxxinity performance evaluation
Checking the ongoing alerts about Vaxxinity for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Vaxxinity help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vaxxinity is way too risky over 90 days horizon | |
| Vaxxinity has some characteristics of a very speculative penny stock | |
| Vaxxinity appears to be risky and price may revert if volatility continues | |
| Vaxxinity is showing solid risk-adjusted performance over 90 days | |
| Net Loss for the year was (56.93 M) with loss before overhead, payroll, taxes, and interest of (1.87 M). | |
| Vaxxinity currently holds about 128.23 M in cash with (57.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 51.0% of the company outstanding shares are owned by insiders |
- Analyzing Vaxxinity's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vaxxinity's stock is overvalued or undervalued compared to its peers.
- Examining Vaxxinity's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vaxxinity's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vaxxinity's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vaxxinity's pink sheet. These opinions can provide insight into Vaxxinity's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vaxxinity Pink Sheet Analysis
When running Vaxxinity's price analysis, check to measure Vaxxinity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxxinity is operating at the current time. Most of Vaxxinity's value examination focuses on studying past and present price action to predict the probability of Vaxxinity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxxinity's price. Additionally, you may evaluate how the addition of Vaxxinity to your portfolios can decrease your overall portfolio volatility.